America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2022 #1 **January 7, 2022**

INSIDE:

ABC Issues Statement Regarding CCP after FDA Updates EUA

America's Blood Centers (ABC) published a statement on COVID-19 convalescent plasma (CCP) on January 6th. ABC emphasized its "support [for the] U.S. Food and Drug Administration's (FDA) continued interest in convalescent plasma as a treatment for COVID-19 patients, [but stressed] that operational considerations must be accounted for before CCP can be a readily available treatment for those patients in need," which included:

- "current FDA requirements for the qualification of vaccinated donors for CCP donations severely limits the ability of most blood centers to collect CCP from that important group of individuals. Changes must be made to those requirements before blood centers could operationalize a large-scale collection of CCP once again;
- due to recent changes by FDA to the list of approved antibody screening tests as well as a previous wane in hospital demand for CCP, a very limited supply of CCP currently exists. Given that the newly approved tests are not currently in wide distribution, it will take weeks for participating testing laboratories, suppliers, and blood centers to be ready to resume CCP production;
- the costs to resume CCP collections are significant and the long-term demand for CCP remains uncertain. The United States Government must play a role in ensuring cost recovery funding to blood centers for CCP collections and production as it has in the past and continues to do with other therapies; and
- the nation continues to face blood shortages brought on by challenges in conducting traditional blood drives and the same staffing shortages seen in other healthcare settings. The need to produce CCP must be balanced by the need to continue to provide blood components to patients facing a variety of acute and ongoing medical conditions."

A PDF version of the full statement is available on the ABC public website.

FDA Updates the Emergency Use Authorization (EUA) for CCP. On December 28th, the FDA reissued in its entirety, the March 9, 2021, letter of authorization for the EUA of CCP. The update states that CCP is now only authorized for use in patients with immunosuppressive disease or receiving immunosuppressive treatment and may be administered to these patients in either the inpatient or outpatient setting.

For the revised authorization, "FDA reviewed additional studies including several randomized controlled trials and observational studies, which reported on the use

(continued on page 2)

ABC CCP Statement (continued from page 1)

of COVID-19 convalescent plasma in both the inpatient and outpatient settings. Based on assessment of these data, transfusion of COVID-19 convalescent plasma in hospitalized immunocompetent patients is unlikely to be associated with clinical benefit and the known and potential benefits do not outweigh the known and potential risks in this population. However, evidence supports a potential clinical benefit of transfusion of COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies to treat COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment." CMS will need to create the required billing code for CCP administered in the outpatient setting. Please contact ABC's Director of Regulatory Affairs Jill Evans with questions.

Johns Hopkins Preprint Study. A new preprint study from Johns Hopkins University has been published on MedRxiv. This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer CCP to placebo control plasma in symptomatic adults >18 years positive for SARS-CoV-2 regardless of risk factors for disease progression or vaccine status. The study demonstrated that early administration of high titer CCP reduced outpatient hospitalizations by more than 50 percent, indicating high titer convalescent plasma is an effective early outpatient COVID-19 treatment with the advantages of low cost, wide availability, and rapid resilience to variant emergence from viral genetic drift in the face of a changing pandemic.

The National CCPP19 Convalescent Plasma Project 19 Leadership Team Response to World Health Organization (WHO). The National CCPP19 Convalescent Plasma Project 19 Leadership Team issued a response letter to the WHO regarding the agency's recommendation against the use of CCP.

(Source: ABC Statement, 1/6/22)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail.

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Rita Reik
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $390

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

National Blood Donor Month Begins

Blood Centers across the U.S. have begun the celebration of National Blood Donor Month (NBDM). Each year, blood centers nationwide thank blood donors while raising awareness of the constant need for blood to ensure the availability of the U.S. blood supply during the month of January.

ADRP, an International Division of America's Blood Centers, has developed several resources as part of a customizable toolkit for blood centers to use in their recruitment efforts. The resources include:

- digital assets for social media channels sized for Twitter, Facebook, and Instagram;
- a press release template; and
- Spanish-translated graphics and assets to use with your followers and sponsors to encourage donating blood while working at home.

U.S. Assistant Secretary for Health Admiral Rachel Levine, MD tweeted on December 23rd in the lead-up to NBDM encouraging eligible individuals to donate blood, stating, "[o]ur nation's blood supply is critically low, and your donation can help ensure life-saving medical treatments are available for patients. The ongoing COVID-19 pandemic has led to a significant decline in blood donation, and we need your help to ensure that patients will have blood in the coming weeks and months." Additionally, The U.S. Department of Veteran Affairs also published a blog post submitted by ABC/ADRP recognizing NBDM.

President Richard Nixon proclaimed January 1970 as the first NBDM on December 31, 1969, as requested by Senate Joint Resolution 154, to pay tribute to voluntary blood donors and encourage new donors to join the cause.

WORD IN WASHINGTON

The U.S. Food and Drug Administration (FDA) has announced that the agency has "implemented temporary changes to inspectional activities" as of December 29, 2021, to "ensure the safety of its employees and those of the firms it regulates as the agency further adapts to the evolving COVID-19 pandemic and the spread of the omicron variant." The temporary changes are scheduled to last through January 19, 2022. According to the FDA, "the agency intends to continue mission-critical work but has temporarily postponed certain inspectional activities with the hopes of restarting these activities as soon as possible. The FDA will continue conducting mission-critical foreign inspections and will reassess plans as needed based on its monitoring foreign travel conditions. The agency also is postponing the planning of prioritized surveillance foreign inspection assignments that were scheduled to begin in February 2022. The FDA is also continuing to conduct mission-critical domestic inspections. State inspections under FDA contract have the discretion to make inspection decisions based on their local information. Importantly, the agency is continuing remote foreign supplier verification program activities for human and animal foods, as well as leveraging other remote tools to maintain oversight of foods, drugs, medical products and tobacco."

(Source: FDA Announcement, 12/29/21)

Senator Amy Klobuchar (D-Minn.) recently led a virtual roundtable to spread awareness for blood donation in attempt to help "alleviate" blood shortages across the state of Minnesota. "Hospitals rely on community donations for their blood supply, but right now Minnesota's blood bank donations are at a

(continued on page 4)

WORD IN WASHINGTON (continued from page 3)

10-year low," said Sen. Klobuchar in a news release. "The good news is that we can help solve this problem by donating blood and encouraging our loved ones to do the same. By coming together to tackle this blood shortage, we can make sure that our state's medical professionals are able to continue their lifesaving work." Other roundtable participants included representatives from Memorial Blood Centers and the American Red Cross. The news release also stated that, "Minnesota's blood banks report that donations have dropped 10 percent since the start of the coronavirus pandemic, and the cold weather, busy schedules, and rise in coronavirus cases are making it difficult to regain the supply that's been lost over the past two years. In some cases, hospital blood inventories have been reduced by 20 percent."

(Source: Sen. Amy Klobuchar News Release, 1/3/22)

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), announced that the administrative hold has been removed from a NHLBI-funded clinical trial at Boston Children's Hospital of a Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease. The lifting of the hold comes in the wake of a "review of the recommendation of the NHLBI Gene and Cell Therapy Data and Safety Monitoring Board (DSMB), which was informed by a thorough examination of safety information and extensive expert consultations." Additionally, the agency "took several important steps to further ensure the safety of research participants and the scientific integrity of the research. Specifically, NHLBI performed a comprehensive assessment of available safety information, including convening, and soliciting input from multidisciplinary scientific and clinical perspectives, as well as patient perspectives…The insights gained through these deliberations enabled the investigators to supplement their existing plans to further minimize risks to research participants (Risk Mitigation Plan). This plan has since been reviewed by the DSMB and the U.S. Food and Drug Administration (FDA) and was implemented for screening potential participants and following up participants already enrolled. The Risk Mitigation Plan was reviewed carefully by an independent panel of cancer genomics experts. These experts provided their findings to the study's DSMB on Sept. 10, 2021, for review. Following its review of this panel's report and other data, the DSMB recommended lifting the administrative hold placed on the trial. The NHLBI accepted the recommendation."

(Source: NHLBI Announcement, 12/27/21)

Carole Johnson has been named administrator of the Health Resources Services Administration (HRSA). Ms. Johnson previously served as the testing coordinator for the White House COVID-19 response team. U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra, JD stated in an agency news release, "With Carole Johnson's return, HHS gains a leader for its Health Resources and Services Administration with deep health expertise who has been integral to the Biden-Harris Administration's fight against COVID-19. Not only does Carole know how to leverage the most effective tools to battle the most pressing public health challenges, she has a strong track record of getting results at the state and national level. In New Jersey, as state Human Services Commissioner, Carole successfully expanded access to health services and demonstrated a strong commitment to health equity. Under President Obama, she was a key leader in government-wide responses to the emergence of Ebola and Zika and to addressing the opioid crisis and other behavioral health challenges and, most recently under President Biden, she has corralled medical personnel and first responders to turn the Delta tide across COVID-19 hot spots. In her new role, the Biden-Harris Administration and our nation will continue to benefit from Carole's experience and policy acumen."

(Source: HHS News Release, 12/17/21)

(continued on page 5)

WORD IN WASHINGTON (continued from page 4)

FDA and the Office of the Assistant Secretary for Preparedness and Response within HHS issued an update on December 31st that allocation and orders on monoclonal antibody therapies were resuming following a temporary pause that had been previously announced on December 23rd amid concerns of the therapies' effectiveness against the Omicron variant of concern (VOC). The agencies stated, "In light of recent National Institutes of Health (NIH) clinical guidelines published on Dec. 30, 2021, and the significant variability in prevalence of the Omicron VOC, all states and territories can continue to order both Lilly (bamlanivimab plus etesevimab) and Regeneron (casirivimab plus imdevimab) monoclonal antibody products from HHS based on allocated amounts for clinically appropriate use. Additionally, jurisdictions, providers and patients should be aware that there are a number of alternative therapeutics, including oral and IV antivirals in addition to the GSK/Vir (sotrovimab) monoclonal antibody that are effective in the face of the Omicron variant. If the Delta VOC still represents a significant proportion of infections in a region and other options are not available or are contraindicated, eligible patients can be offered bamlanivimab plus etesevimab or casirivimab plus imdevimab, with the understanding that these treatments would be ineffective if the patients are infected with the Omicron VOC."

(Source: FDA and ASPR Joint Statement, 12/31/21) ♦

RESEARCH IN BRIEF

Factors Influencing Hemoglobin Content in Red Blood Cells. A study in *Transfusion and Apheresis Science* looked at the "differences in the processing procedures used, manufacturing, and types of leukocyte-reduction filter influence characteristics of the final product." The authors explained that, "[t]he study was done [using 260 red blood cell (RBC) units] to analyze the variation of the hemoglobin content in collected RBC units and factors influencing it…The donors [met] screening criteria per the Indian Blood Bank standards, hemoglobin (12.5-18 g/dl)…The RBC units were separated based on the volume collected i.e., 350 mL or 450 mL and processing method [platelet rich plasma (PRP) vs buffy coat (BC)]…[A] "[b]lood sample from the unit [was] tested for hematological parameters." The investigators performed a "regression analysis [to] estimate [the] significance of independent variables with hemoglobin content...The mean hemoglobin was 54.7 g [range] 34.2–80 g…There was a statistically significant association ($p < 0.0001$) of capillary hemoglobin, gender and weight of the donor with the total hemoglobin of the RBC unit…Capillary hemoglobin of the donor showed a strong association with gender ($p < 0.0001$) but not with age or weight of the donor…The mean hemoglobin for 350 mL volume bag was 48 g and for 450 mL bag was 63 g ($p < 0.001$)…Similarly, the mean hemoglobin for RBC units separated by PRP method was 58 g and by BC method was 51 g ($p < 0.001$)." The study found that, "[a]ll the four groups showed significant difference ($p < 0.0001$) with respect to their mean hemoglobin content…The type of bag used significantly influenced the hemoglobin ($p < 0.0001$) but there was no significant difference in relation to the final red cell volume…The capillary hemoglobin, type of bag (processing method) and volume of bag were factors which showed a strong correlation and significantly influenced the total hemoglobin content ($p < 0.0001$)…[A] regression analysis showed all three contributed to 80 percent variability of hemoglobin content in the RBC unit." The authors concluded that "[t]here is a need for labelling and transfusion of RBC units based on their hemoglobin content for better transfusion practice and patient care management."

Citation: Rudrappan, R.B., Gupta, D., Mohan, L. A comparative analysis of factors influencing haemoglobin content in RBC units. *Transfusion and Apheresis Science*. 2021.

Contributed by Richard Gammon, MD, Medical Director at OneBlood ♦

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

ABC Members Asked to Complete Annual Collection Survey

The America's Blood Centers (ABC) Annual Collection Survey for calendar year 2021 has been distributed. ABC Member blood centers are asked to complete the survey by January 28th. A link to the survey and a copy of the survey questions are available in MCN 22-001. Please contact Member Services with any questions.

December ABC *Blood Bulletin* Available

ABC's Scientific, Medical, and Technical (SMT) Publications Committee has published the December 2021 Issue of the *Blood Bulletin*, titled "Today's Platelet Products — Not Your Grandfather's Platelets." The article was written by Richard Gammon, MD, Medical Director at OneBlood; Courtney Hopkins, DO, Senior Chief Medical Officer at Vitalant; Debra Smith, MD, PhD, Associate Medical Director at Oklahoma Blood Institute; Nancy Van Buren, MD, Medical Director at Innovative Blood Resources, a division of New York Blood Center; and Claudia Cohn, MD, PhD, Professor of Laboratory Medicine and Pathology, Medical Director of the Blood Bank, Associate Director of Clinical Laboratories at the University of Minnesota. The *Blood Bulletin* is reviewed and edited by ABC's SMT Publications Committee. ABC publishes the *Blood Bulletin* for use by member blood centers in their educational programs as a value-added service for hospital customers. Please contact Member Services for trouble accessing the publication.

(Source: MCN 21-104, 12/14/21)

Register for the 60th ABC Annual Meeting

Register today for the 60th ABC Annual Meeting and 25th Annual *Awards of Excellence.* These events will take place March 7th-9th, 2022 at the Ritz-Carlton (Pentagon City) in Arlington, Va. Please secure your hotel reservation today. This year's meeting will be in-person while Advocacy Day will be held virtually the following week given continued visitor restrictions on Capitol Hill. This will allow each blood center to bring together multiple colleagues to connect with their members of Congress and their staff. More information will be provided to ABC members as it becomes available. The ABC Annual Meeting brings together blood center executives and national leaders to discuss advocacy and regulatory updates, the latest in science, medicine, and technical affairs, and hot topics facing the blood community. In addition, ABC is excited to share that the final day of this year's meeting will feature two in-depth training workshops focused on building tangible advocacy skills that can immediately benefit your center. The program-at-a-glance is available. Please contact ABC Member Services with questions.

PEOPLE

Graham Sher, MD, PhD, chief executive officer of Canadian Blood Services, has been appointed an Officer of the Order of Canada by the Governor General. The honor recognizes his "contributions to public health and for being instrumental in the development of Canada's largest blood system operator." In an announcement recognizing Dr. Sher's achievement, he stated, "I've been in Canada for 31 years, but I am an immigrant," he says. "That Canada would seek to hon[o]r me with one of its highest orders, for those who have made it a better country, is very moving." According to a description of the honor, "the Order of Canada recognizes outstanding achievement, dedication to the community and service to the nation. More than 7,000 people from all sectors of society have been invested into the Order. Those who bear the Order's iconic snowflake insignia have changed our nation's measure of success and, through the sum of their accomplishments, have helped us build a better Canada. Appointments are made by the governor general on the recommendation of the Advisory Council for the Order of Canada."

(Source: Canadian Blood Services Announcement, 12/29/21)

GLOBAL NEWS

The Irish Blood Transfusion Service (IBTS) announced forthcoming changes to the deferral policies for men who have sex with other men (MSM). According to a news release from the IBTS, the changes will take place in two phases with the first scheduled to begin by the end of March and the second phase to be implemented later in 2022. "The initial phase will reduce the existing 12-month deferral for MSM to four months. This is an interim measure while the IBTS introduces new technology, to replace the existing paper health and lifestyle questionnaire (HLQ) with an electronic questionnaire known as the Self-Assessment Health History (SAHH). This will enable phase two, the introduction of an individual assessment process for donors, thus making blood donation more inclusive. The individual assessment of donors' sexual behavi[o]r will be similar to the FAIR (For the Assessment of Individuali[z]ed Risk) system introduced by the UK Blood Services. The deferral of any person who is taking pre-exposure prophylaxis (PrEP) will also be reduced from 12 months to four months and this deferral will remain in place after the introduction of the individual assessment." The changes come in the wake of a report from an independent advisory group, established by IBTS that included IBTS Donor Consultants, Infectious Disease Physicians, Public Health Physicians, an Epidemiologist, and the IBTS Risk & Resilience Manager in addition to stakeholders from the Irish Haemophilia Society, Sickle and Thalassemia Ireland, and HIV Ireland. IBTS Medical and Scientific Director Professor Stephen Field added in the news release, "[t]he independent advisory committee commenced its work in early 2021.The remit of this advisory committee was to review the current evidence base for donor eligibility in Ireland relating to factors that may increase the risk of a donor acquiring specific blood borne infections (HIV, HBV, HCV and other sexually transmitted infections). As always maintenance of the safety of the Irish blood supply for all recipients is our primary concern."

(Source: Irish Blood Transfusion Service News Release, 12/20/21)

The World Health Organization (WHO) issued an interim statement on booster doses of the COVID-19 vaccination as it continues to encourage member nations to prioritize vaccination efforts on global access for the primary series of COVID-19 vaccinations before focusing on booster doses. According

(continued on page 8)

GLOBAL NEWS (continued from page 7)

to the statement from the WHO with support from the Strategic Advisory Group of Experts (SAGE), "[i]n the context of ongoing global vaccine supply constraints and inequities, broad-based administration of booster doses risks exacerbating vaccine access by driving up demand in countries with substantial vaccine coverage and diverting supply while priority populations in some countries, or in subnational settings, have not yet received a primary vaccination series. Introducing booster doses should be firmly evidence-driven and targeted to the population groups at highest risk of serious disease and those necessary to protect the health system…More data will be needed to understand the potential impact of booster vaccination on the duration of protection against severe disease, but also against mild disease, infection, and transmission, particularly in the context of emerging variants…SAGE will further discuss policies to optimize the use of vaccines including the consideration of booster vaccination at its forthcoming meeting on January 19th."

(Source: WHO Statement, 12/22/21)

Upcoming ABC Webinars – Don't Miss Out!

- **Bacterial Contamination of Platelets for Transfusion Webinar** – Recording available.
- **Paid Donors-Platelet and Cellular Therapy Blood Center Perspectives Webinar** – February 15th from 3-4:30 PM ET. More information coming soon.

COMPANY NEWS

Terumo Blood and Cell Technologies and ADRP, an International Division of America's Blood Centers, issued a joint news release highlighting resources promoting awareness of the need for blood and encouraging individuals to donate blood regularly as National Blood Donor Month begins. Through a grant from Terumo, ADRP produced educational videos urging eligible individuals to donate and "developed a robust social media and communication toolkit for blood centers worldwide" to spread blood donation awareness. "One blood donation can help many patients on their journey, and it's critical to offer blood centers the tools they need to help collect this precious resource," said Terumo Blood and Cell Technologies General Manager Chetan Makam in the joint news release. ADRP Executive Director Carla Peterson added, "ADRP continues working to deploy plug-and-play resources that blood centers can use immediately…We hope tapping social media will inspire Millennials and Gen Z to step up and donate blood."

(Source: Terumo Blood and Cell Technologies & ADRP Joint News Release, 1/4/22)

Grifols has acquired its first plasma collection center in Canada. The acquisition of Prometic Plasma Resources Inc's in Winnipeg adds to the company's Canadian footprint and "commitment to increase the availability of lifesaving plasma medicines in the country." This follows the 2020 purchase of [a] plasma fractionation plant with an annual capacity of 1.5 million liters and two purification facilities. The production plants are currently being developed and are expected to be operational in 2023."

(Source: Grifols News Release, 1/4/22)

The U.S. Food and Drug Administration (FDA) has placed a clinical hold for patients under the age 18 of in the clinical trials for **bluebird bio, Inc.'s** investigational gene therapy (lovotibeglogene autotemcel) to

(continued on page 9)

COMPANY NEWS (continued from page 8)

treat sickle cell disease (SCD). According to the announcement form bluebird bio, "the partial, temporary suspension relates to an ongoing investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with [the investigational gene therapy], now 18 months post-treatment. This patient is clinically well and there is no evidence of malignancy or clonal predominance…Consistent with the FDA's clinical hold procedures, bluebird anticipates receiving written questions from the agency in early 2022 and will work quickly to respond in order to resolve the partial hold." The company did state that enrollment and dosing for SCD patients over the age of 18 in the clinical trials will continue.

(Source: bluebird bio, Inc. News Release, 12/20/21)

Valneva recently announced "positive topline results" from a phase III lot to-lot trial of its single-shot chikungunya vaccine candidate. A company news release reported that the trial "met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent immune responses measured by neutralizing antibody titer GMT ratios on Day 29 after vaccination…The trial, which included 408 participants aged 18 to 45 years…[the vaccine candidate was] equally well tolerated and the safety profile was consistent with results in [another] phase III trial being conducted by Valneva...The lot-to-lot trial will continue towards final six-month analysis with final trial results expected in the second quarter of 2022. Valneva's chikungunya program was awarded Breakthrough Therapy Designation by the [FDA] in July 2021."

(Source: Valneva News Release, 12/21/21)

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2022

Mar. 7-9. **ABC Annual Meeting, Washington, D.C.** Registration is open. More information available here.

Mar. 15-16. **International Plasma and Fractionation Association (IPFA) and the European Blood Alliance (EBA) Symposium on Plasma Collection and Supply, Amsterdam, the Netherlands.** Registration is open. More information available here.

April 5-7. **ABC Technical and Quality Workshop, Louisville, Ky.** More information available here.

April 12-13. **17th Annual FDA and the Changing Paradigm for HCT/P Regulation, Cambridge Md.** Registration is open. More information available here.

May 10-12. **2022 ADRP Conference, Phoenix, Ariz.** Registration is open.

June 4-8. **37th Annual International Congress of ISBT, Kuala Lumpur, Malaysia.** Additional details coming soon.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Therapeutic Apheresis Nurse. LifeSouth Community Blood Centers is currently seeking an experienced professional to join our team as a Therapeutic Apheresis Nurse in **Jacksonville, FL**. This position is responsible for traveling to hospitals to perform apheresis procedures. Nurses will only care for one patient at a time and will work alongside hospital nurses and physicians to complete procedures. Nurses will also spend time at the LifeSouth office to coordinate upcoming apheresis procedures and organize necessary documentation. Training: Don't let a lack of apheresis experience stop you from applying! No previous apheresis experience is required. If hired, you will be given sufficient on-the-job training to learn the specialized skills this position requires. Training for this position will be conducted during regular business hours. This is a full-time position. Starting salary range is $60,000 - $66,000 annually plus travel and on-call bonus. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. Applicants should apply here: https://lifesouth.csod.com/ux/ats/careersite/5/home/requisition/2490?c=lifesouth

Therapeutic Apheresis Nurse. LifeSouth Community Blood Centers is currently seeking an experienced professional to join our team as a Therapeutic Apheresis Nurse in **Gainesville, FL**. This position is responsible for traveling to hospitals to perform apheresis procedures. Nurses will only care for one patient at a time and will work alongside hospital nurses and physicians to complete procedures. Nurses will also spend time at the LifeSouth office to coordinate upcoming apheresis procedures and organize necessary documentation. Training: Don't let a lack of apheresis experience stop you from applying! No previous apheresis experience is required. If hired, you will be given sufficient on-the-job training to learn the specialized skills this position requires. Training for this position will be conducted during regular business hours. This is a full-time position. Starting salary range is $60,000 - $66,000 annually plus travel and on-call bonus. Background check and drug test required. Equal Opportunity/Affirmative Action Employer/DFWP/Tobacco Free. **Applicants should apply here:** https://lifesouth.csod.com/ux/ats/careersite/5/home/requisition/2489?c=lifesouth

QRA Supervisor (Req#: R219667). Reporting to the Regulatory & Accreditation Compliance Director, the QRA Supervisor is responsible for carrying out day-to-day activities at the Stanford Blood Center Quality & Regulatory Affairs department by appropriate management of the QRA Specialist, ensure timely review of records and completion of QRA activities. Assume the responsibility SBC safety initiatives, disaster preparedness, and support continuity of operation across the organization. Responsibilities: Quality Assurance/Training/ GMP/GTP/GLP: Lead the department's quality activities, initiatives, and process improvement activities. Perform training on QRA core functions and activities, Good Manufacturing Practice/Good Tissue Practice/Good Laboratory Practice, and safety. Compliance: Ensure compliance to current regulations and accreditation requirements by federal, state, county, and accreditation agencies. Team Leadership: Manage the performance of direct reports. Set team objectives, priorities, and resources to align staff with Blood Center objectives. Responsible for inter-viewing, hiring, training, coaching, performance management, and performance reviews of direct reports. Safety: Lead the safety, emergency, and disaster management. Quality Management System: Provide over-sight on the appropriate use of the quality management tools in handling the various documents, records, and activities of the blood center. Qualifications: Bachelor's Degree Required. One to two years supervisory experience in a regulated or GMP (Good Manufacturing Practice) required. Click here to apply.

Director, Strategic Communications and National Partnerships. America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a Director, Strategic Communications and National Partnerships. The position is a key role in a new area of work for ABC and will lead the development and execution of a comprehensive strategy and tools to motivate action by the public and key stakeholders related to blood donation and the need for blood donors. The position will also direct ABC's digital, social, and traditional media affairs, including content creation, and implementation of communication strategies to promote the association's advocacy agenda and increase members' engagement with their elected officials. The position will report directly to the Chief Executive Officer. Responsibilities: Oversee the development of integrated public action and advocacy campaigns that drive significant shifts in how stakeholders view, understand, and support blood donation. Facilitate dialogue and coordinated and aligned messaging, tools, and activities to maximize engagement with strategic partners and the public to promote blood donation. Develop and nurture relationships and accelerate collaboration with national partners to increase base of support. Educational Requirements: Bachelor's required. Experience, Knowledge, Skills and Abilities: Seven plus years of experience with communications and media relations, campaign execution, and partnership development. Click here to view the full job description. Interested applicants should send a cover letter and resume to careers@americasblood.org.

Clinical Lab Scientist 1. The College of Medicine, Hoxworth Blood Center is recruiting a Clinical Laboratory Scientist 1 in the Quality Control Laboratory. This position will support the University's mission and commitment to excellence and diversity in our students, faculty, staff, and all our activities. Clinical Laboratory

(continued on page 11)

POSITIONS (continued from page 10)

Scientist 1 will perform routine and complex quality control testing of blood and blood components, as well as high-level evaluation, review, and interpretation of test results. Candidates shall be able to perform with minimal supervision, be proficient in computerized data entry and retrieval functions, and communicate effectively with individuals within and outside the department. This position will be trained on first shift and assigned to work on the second shift after training is completed. Required Education: Bachelor's Degree in Medical Technology, Medical Laboratory Sciences, or other related biological science. Four (4) years of relevant work experience and/or other specialized training can be used in lieu of education requirement. Required Trainings/Certifications: Some labs require MLT(ASCP), MLS(ASCP), MT(ASCP), BB(ASCP), or SBB(ASCP). The University of Cincinnati is an Affirmative Action / Equal Opportunity Employer / Minority / Female / Disability / Veteran. Apply today at Hoxworth Blood Center Hoxworth Blood Center (uc.edu). ♦